SynthesisFrontiers in psychiatry2026
Effects of trazodone on polysomnographic sleep architecture in patients with depression and sleep disorders: a systematic review and exploratory meta-analysis.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sleep disturbance and cognitive impairment are common in depression. Trazodone is often used for sleep problems and may improve cognition by modifying sleep architecture. However, its effects on specific polysomnography-derived sleep stages remain unclear. This systematic review and exploratory meta-analysis aimed to investigate trazodone's effects on sleep architecture in patients with depression and sleep disorders. Methods: Seven databases were searched for interventional studies published up to October 2025. Random-effects models were applied to estimate pooled mean differences (MDs) and risk ratios (RRs), as appropriate. Results: Eight studies involving 980 patients were included: five randomized controlled trials and three single-arm studies. Compared with baseline, trazodone was associated with increased total sleep time and sleep efficiency, and with reduced sleep latency. Regarding sleep architecture, trazodone was linked to reduced non-rapid eye movement sleep stage 2 (N2) proportion (MD = -9.09, 95% CI -16.60 to -1.59, P = 0.017) and increased slow wave sleep (SWS) proportion (MD = 8.05, 95% CI 3.42 to 12.68, P = 0.001). No significant effects were observed for wake after sleep onset, NREM stage 1 percentage, rapid eye movement sleep percentage (REM), and REM sleep latency. Secondary outcomes suggested reduced HAMD-17 scores and higher response rates versus placebo, but more adverse events, especially somnolence and dizziness, with trazodone. Conclusion: Trazodone may improve objective sleep continuity and may be associated with changes in sleep architecture, including increased SWS and reduced N2 sleep, in patients with depression, without significantly altering REM sleep. These potential benefits should be weighed against increased adverse events. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251173354.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.